Agios Pharma (AGIO) AI Stock Analysis

• Market Cap: $2.28B
• Dividend Yield: N/A
• Average Volume (3M): 862.36K
• Price to Earnings (P/E): 3.7
• Beta (1Y): 1.73
• Revenue Growth: 30.57%
• EPS Growth: N/A
• Country: US
• Employees: 486
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -1.93
• Shares Outstanding: 58,101,517
• 10 Day Avg. Volume: 589,483
• 30 Day Avg. Volume: 862,356
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 51.14
• P/FCF Ratio: -4.77
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 25.36
• Enterprise Value/Gross Profit: 29.80
• Enterprise Value/Ebitda: -2.34
• 1Y Price Target: $51.33
• Price Target Upside: 42.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 60 Neutral
• Price Target: $38.00 ▲(5.18% Upside)

Agios Pharma's overall stock score reflects a mix of strengths and challenges. The company's strong equity position and recent positive corporate events are offset by operational profitability issues and liquidity concerns. The stock's undervaluation and positive earnings call sentiment provide some upside potential, but investors should be cautious of the financial performance risks.

Positive Factors

Approval Process

The request for a REMS rather than an outright CRL or request for more safety data is a positive sign that the FDA will approve Pyrukynd for thal.

International Approvals

Saudi FDA approval for Pyrukynd in thalassemia is seen as a positive development.

Market Potential

Mitapivat is expected to be tried by up to 50% of transfusion-dependent patients within 5 years, especially as a first step in treatment before gene therapy.

Negative Factors

Adverse Events

AGIO shares appear to have been under pressure from three deaths in Pyrukynd patients that newly appeared in the FDA’s FAERS database.

Drug Monitoring

In both of these newly added patients the reporter deems Pyrukynd as most likely to be associated with the event, the stronger of the two endorsement levels available in FAERS.

Safety Concerns

It is difficult to fully dismiss the impact of the safety concerns on the PDUFA, especially if other non-fatal FAERS entries suggest a risk for liver injury.

Agios Pharma Business Overview & Revenue Model

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Agios Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, particularly ivosidenib, which has been approved by regulatory authorities and is marketed to healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical companies that may involve co-development or commercialization agreements. These partnerships often provide upfront payments, milestone payments based on the achievement of specific development or sales targets, and royalties on future sales. Additionally, Agios may receive funding from research grants or government initiatives aimed at supporting the development of therapies for rare diseases.

Agios Pharma Financial Statement Overview

Summary

Agios Pharma shows significant operational challenges with negative EBIT and EBITDA margins, reflecting substantial losses. A strong equity position is overshadowed by negative cash flow and profitability, posing financial risks.

Income Statement

Agios Pharma's income statement shows significant volatility with negative EBIT and EBITDA margins, indicating operational challenges. Despite recent revenue growth, net profit margins remain negative, reflecting substantial losses. The company's gross profit margin is positive, but overall profitability is impacted by high operational costs.

Balance Sheet

The balance sheet reveals a strong equity position with a low debt-to-equity ratio, indicating financial stability. However, the return on equity is negative due to consistent net losses, which could be concerning if trends don't reverse. The equity ratio is solid, suggesting good asset coverage by equity.

Cash Flow

Cash flow analysis points to negative operating cash flow, indicating potential liquidity issues. Free cash flow remains negative, though there's a positive trend in free cash flow growth recently. The operating cash flow to net income ratio is unfavorable, highlighting the need for improved cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.88M	36.50M	26.82M	14.24M	0.00	203.20M
Gross Profit	34.79M	32.33M	17.32M	12.54M	-18.78M	200.39M
EBITDA	-442.59M	-425.74M	-384.86M	-380.48M	-337.73M	-326.13M
Net Income	650.08M	673.73M	-352.09M	-74.56M	1.60B	-335.22M
Balance Sheet
Total Assets	1.47B	1.66B	937.12M	1.24B	1.44B	852.95M
Cash, Cash Equivalents and Short-Term Investments	938.94M	893.71M	776.93M	1.10B	1.29B	670.54M
Total Debt	48.76M	56.99M	72.00M	85.66M	97.09M	105.20M
Total Liabilities	101.68M	122.24M	126.10M	137.90M	145.76M	453.45M
Stockholders Equity	1.37B	1.54B	811.02M	1.10B	1.29B	399.50M
Cash Flow
Free Cash Flow	-409.02M	-391.53M	-297.06M	-314.36M	-413.06M	-305.67M
Operating Cash Flow	-406.00M	-389.84M	-296.06M	-309.48M	-407.32M	-290.76M
Investing Cash Flow	393.19M	363.44M	239.57M	243.26M	1.25B	75.75M
Financing Cash Flow	9.16M	14.44M	5.43M	2.35M	-765.77M	261.52M

Agios Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 36.13
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGIO, the sentiment is Negative. The current price of 36.13 is below the 20-day moving average (MA) of 37.40, below the 50-day MA of 37.39, and above the 200-day MA of 35.67, indicating a neutral trend. The MACD of 0.39 indicates Negative momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 70.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AGIO.

Agios Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAMS	61 Neutral	$2.77B	―	-28.43%	―	―	―
AGIO	60 Neutral	$2.28B	3.68	64.05%	―	30.57%	―
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
RXRX	50 Neutral	$2.03B	―	-86.34%	―	30.14%	-10.08%
APGE	49 Neutral	$2.26B	―	-34.12%	―	―	-79.09%
IBRX	46 Neutral	$2.26B	―	78.99%	―	4227.22%	50.80%
DNLI	45 Neutral	$2.26B	―	-39.69%	―	-100.00%	1.62%

Agios Pharma Corporate Events

Agios Pharma’s PYRUKYND Approved by Saudi Authority

Agios Pharmaceuticals addressed a recent securities analyst report detailing adverse event data from the FDA’s reporting system concerning its drug PYRUKYND. The report highlighted four patient cases, but Agios maintains that the information has not changed the drug’s established benefit-risk profile. The company continues to prioritize patient safety through rigorous pharmacovigilance processes. Additionally, on August 4, 2025, the Saudi Food and Drug Authority approved PYRUKYND for treating adult patients with specific types of thalassemia, potentially expanding its market reach.

Agios Pharma Appoints Dr. Jay Backstrom as Director

On July 3, 2025, Agios Pharmaceuticals announced the election of Dr. Jay Backstrom as a class III director, effective July 8, 2025, with a term lasting until the 2028 Annual Meeting of Stockholders. Dr. Backstrom will also join the Science and Technology Committee and receive compensation in line with the company’s non-employee director policy, including cash compensation and stock options. This strategic addition to the board is expected to enhance Agios’s focus on scientific and technological advancements, potentially impacting its market positioning and stakeholder relations positively.

Agios Pharma Increases Shares in Stock Incentive Plan

At the 2025 Annual Meeting of Stockholders held on June 18, Agios Pharmaceuticals’ stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,500,000. Additionally, the stockholders elected two directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year, reflecting strong support for the company’s strategic direction.